SequelSEC

Vivos Therapeutics, Inc. VVOS

Surgical & Medical Instruments & Apparatus · CIK 0001716166 · Fiscal year ends 1231

Revenue
$20.90M
Fiscal year ended 2026-06-30
Operating income
-$22.56M
Fiscal year ended 2026-06-30
Free cash flow
-$19.01M
Fiscal year ended 2026-06-30

Valuation, from the filing

Public float$22.90MMarket value of stock held by non-affiliates, as stated on the cover page for 2025-06-30
Float per share$1.70Float divided by shares outstanding in the same filing. A floor under the share price on that date, not the price itself.
Float / revenue1.3×A lower bound on the multiple, because affiliate holdings are excluded.

Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2025-06-30, not today, and each multiple below it uses the figures for the fiscal year ending 2025-12-31 — the year that filing covered.

How this compares in its industry

Percentile among the Surgical & Medical Instruments & Apparatus filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.

MeasureReportedPercentile
R&D / revenue0.6%3th
Current ratio0.24x9th
CapEx / revenue13.4%88th
Operating margin-114.1%26th
Net margin-121.4%26th
FCF margin-100.9%26th
SBC / revenue3.8%39th
Revenue YoY growth16.0%57th
Gross margin60.4%47th

Vivos Therapeutics, Inc. (VVOS) reported revenue of $20.90M and net income of -$25.46M for the fiscal year ended 2026-06-30. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from Vivos Therapeutics, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Surgical & Medical Instruments & Apparatus.

Income

Vivos Therapeutics, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Revenue$20.90M
Cost of revenueUnavailable
Gross profit$12.94M
Operating income-$22.56M
Net income-$25.46M
Research & developmentUnavailable
Weighted-average diluted sharesUnavailable
Pretax income-$25.63M
Income tax expenseUnavailable
Diluted EPSUnavailable
Selling, general & administrative$33.70M
General & administrative$32.51M
Selling & marketing$1.19M

Balance

Vivos Therapeutics, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Cash & equivalents$1.77M
Total assets$24.14M
Current assets$4.21M
Total liabilities$28.13M
Current liabilities$20.39M
Total equity incl. NCI-$3.99M
Temporary (mezzanine) equityUnavailable
InventoryUnavailable
Accounts receivable$1.44M
Goodwill$8.57M
Long-term debt$366.00K
Accounts payable$2.95M

Cash flow

Vivos Therapeutics, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Operating cash flow-$17.13M
Capital expenditures$1.88M
Investing cash flow-$1.93M
Financing cash flow$16.44M
Net change in cash-$2.63M
Stock-based compensation$303.00K
Common dividends paidUnavailable
Common share repurchasesUnavailable
Depreciation & amortization$1.79M

Derived

Vivos Therapeutics, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Free cash flow-$19.01M
Gross margin61.9%
Operating margin-107.9%
FCF margin-91.0%
SBC / revenue1.4%
Current ratio0.21x
Revenue YoY growth45.2%
Net margin-121.8%
R&D / revenueUnavailable
CapEx / revenue9.0%
Long-term debt / equityUnavailable
Effective tax rateUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open VVOS in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-14View SEC filing
10-Q · Filed 2026-05-20View SEC filing
10-K · Filed 2026-04-15View SEC filing
10-Q · Filed 2025-11-19View SEC filing
10-Q · Filed 2025-08-19View SEC filing
10-Q · Filed 2025-05-15View SEC filing

Companies in the same industry

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.